Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 1.39 per share at the end of the most recent trading day (a 18.8% change compared to the prior day closing price) with a volume of 1.39M shares and market capitalization of 74.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.

The one-year performance of Aquestive Therapeutics Inc. stock is -67.95%, while year-to-date (YTD) performance is -64.27%. AQST stock has a five-year performance of %. Its 52-week range is between 0.618 and 6.4, which gives AQST stock a 52-week price range ratio of 13.35%

Aquestive Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 1.11, a price to cashflow ratio of 38.20, a PEG ratio of 2.32, a ROA of -116.65%, a ROC of -107.70% and a ROE of 95.33%. The company’s profit margin is -91.51%, its EBITDA margin is -89.20%, and its revenue ttm is $36.64 Million , which makes it $0.75 revenue per share.

Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $6.5, which is +367.63% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aquestive Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.26, ATR14 : 0.14, CCI20 : 289.14, Chaikin Money Flow : -0.19, MACD : 0.07, Money Flow Index : 89.67, ROC : 72.67, RSI : 64.10, STOCH (14,3) : 88.06, STOCH RSI : 1.00, UO : 51.86, Williams %R : -11.94), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were: A. Mark Schobel (Buy at a value of $44 036), Daniel Barber (Buy at a value of $88 073), Lori J. Braender (Buy at a value of $13 211), Peter Boyd (Buy at a value of $6 251)